´ëÇÑ°£ÇÐȸ APASL STC 2023 DAY 1 : 2023-09-21
±³À°ÀÏÀÚ : 2023-09-21
±³À°Àå¼Ò : ºÎ»ê º¤½ºÄÚ ROOM 1~4
±³À°ÁÖÁ¦ : APASL STC 2023 DAY 1
ÁÖÃÖ±â°ü : ´ëÇÑ°£ÇÐȸ
´ã´çÀÚ : APASL STC Áغñ»ç¹«
¿¬¶ôó : 02-373-1005
À̸ÞÀÏ : apaslstc2023@hbni.co.kr
±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀÎ : 1000¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ºÎ»ê±¤¿ª½Ã
±³À°½Ã°£ : 13 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 320,000¿ø
ºñ°í "Early Bird Registration-APASL Member USD 100/Non-Member USD 150/Trainee / Resident / Researcher / Nurse USD 50/Abstract Presenting Author USD 50/Group (more than 10)USD 50
Regular Registration-APASL Member USD 150/Non-Member USD 200/Trainee / Resident / Researcher / Nurse USD 80/Abstract Presenting Author USD 50/Group (more than 10)USD 80"
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 08:30~08:40 Updates on Epidemiology and Natural Course of Viral Hepatitis in Asian-Pacific Region: HBV Jeong Eun Song(Daegu Catholic Univ., Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 08:40~08:50 Updates on Epidemiology and Natural Course of Viral Hepatitis in Asian-Pacific Region: HCV Nae-Yun Heo(Inje Univ., Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 08:50~09:00 Clinical Impacts of Epidemiological Growth of NAFLD in Asian-Pacific Region Young Youn Cho(Chung-Ang Univ., Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 09:00~09:10 Cure of Viral Hepatitis: Definition and Sub-Classification Hyun Young Woo(Pusan National Univ., Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 09:10~09:20 Overview of Barriers to HBV Cure Eun Young Cho(Wonkwang Univ., Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 09:20~09:40 Overview of Barriers to HCV Cure Tae-Hee Lee(Konyang Univ., Korea)
Åä·Ð 09¿ù 21ÀÏ ROOM 1 09:40~09:50 Discussion ()
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 10:20~10:50 Asian-Western Collaborations Toward Elimination of Viral Hepatitis W. Ray Kim(Stanford Univ., USA)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 10:50~11:05 HBV 2023: New Therapeutic Strategies against an Old Foe Sang Hoon Ahn(Yonsei Univ., Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 11:05~11:20 HCV 2023: The Road to Elimination of HCV Yasuhito Tanaka(Kumamoto Univ., Japan)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 11:20~11:35 Optimizing Hepatitis B and C Treatment in Resource-Limited Settings Diana A. Payawa(Fatima Medical Univ., Philippines)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 11:35~11:50 Global Care Cascade for Chronic Hepatitis B and C Virus Infection Ming-Lung Yu(Kaohsiung Medical Univ., Taiwan)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 12:50~13:20 A 30-Year Journey of HCV Research: From Discovery to a Cure Raymond T. Chung(Harvard Univ., USA)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 13:20~13:40 Notable Milestones Achieved for Viral Hepatitis Elimination to Date Jose Sollano(The Univ. of Santo Tomas, Philippines)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 13:40~14:00 Efforts and Strategy to Accelerate Progress Toward Viral Hepatitis Elimination by 2030 Jinlin Hou(Southern Medical Univ., China)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 14:00~14:20 It Is Time for a Simplified Approach to Hepatitis B Elimination Young Suk Lim(Univ. of Ulsan, Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 14:40~15:00 When to Stop Nucleos(t)ide Analogues: Risks and Benefits Jordan Feld(Univ. of Toronto, Canada)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 15:00~15:20 Application of Current Biomarkers to Guide Anti-HBV Treatment Tetsuya Hosaka (Toranomon Hospital, Japan)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 15:20~15:40 Can Antivirals Reduce Intrahepatic cccDNA and Integrated HBV DNA? Marc G. Ghany(NIH, USA)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 15:40~16:00 Risk of HCC and Biomarkers after a Cure of Hepatitis B Jeong Won Jang(The Catholic Univ. of Korea, Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 16:20~16:40 Current Optimal Treatment for Chronic HCV Infection in Various Clinical Situations Jung Il Lee(Yonsei Univ., Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 16:40~17:00 Strategies for the Elimination of HCV Infection Norah Terrault(Univ. of Southern California, USA)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 17:00~17:20 Current and Emerging Therapeutic Approaches to HDV Infection Maria Buti Ferret (Hospital Universitario Valle Hebron, Spain)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 1 17:20~17:40 HBV-HCV Dual Infection: Changing Epidemiology and Treatment in Asia Chun-Jen Liu(National Taiwan Univ., Taiwan)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 2 10:50~11:00 Cost-Effectiveness HCV Screening and Treatment in South Korea Sook-Hyang Jeong(Seoul National Univ., Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 2 11:00~11:10 Clinical Challenges in HCV Management in Japan Atsumasa Komori(Nagasaki Univ., Japan)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 2 11:10~11:20 How Would China Achieve WHO Lai Wei(Tsinghua Univ., China)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 2 11:20~11:30 Linkage-to-Care and Follow-Up Strategy for HCV Infection in Taiwan Tai-Chung Tseng(National Taiwan Univ., Taiwan)
Åä·Ð 09¿ù 21ÀÏ ROOM 2 11:30~11:50 Discussion ()
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 2 14:40~15:00 Immunological Characteristics of HBV Infection Antonio Bertoletti(Duke-NUS Medical School, Singapore)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 2 15:00~15:20 Immunological Scar after HCV Clearance Eui-Cheol Shin(KAIST, Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 2 15:20~15:40 T-Cell Responses against Hepatitis Viruses in Human Liver Hideki Ueno(Kyoto Univ., Japan)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 2 15:40~16:00 Novel Immunological Therapeutics for Cure of HBV Infection Wonseok Kang(Sungkyunkwan Univ., Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 2 16:20~16:40 Updates on Drugs for HBV Entry and/or Post-Entry Inhibition Hyung Joon Yim(Korea Univ., Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 2 16:40~17:00 Updates on HBV Capsid Assembly Inhibitors Robert Gish(The Univ. of Nevada, USA)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 2 17:00~17:20 Updates on Drugs Targeting HBV RNAs: ASOs and siRNA Jidong Jia(Capital Medical Univ., China)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 2 17:20~17:40 Updates on cccDNA Disruptors Jin-Wook Kim(Seoul National Univ., Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 3 13:20~13:35 Novel Blood-Based Biomarkers for Diagnosis of HCC in Chronic Viral Hepatitis Jaeyoun Cheong(Ajou Univ., Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 3 13:35~13:50 TERT Alterations in Virus-Induced Hepatocarcinogenesis: Actionable Target? Ju Hyun Shim(Univ. of Ulsan, Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 3 13:50~14:05 Molecular Signature and Immune Landscape of among HBV, HCV, and Non-Viral HCCs Young-Sun Lee(Korea Univ. Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 3 14:05~14:20 Differential T-Cell Function between Viral and Non-Viral HCC during Immuno-Oncologic Therapy Ji Won Han(The Catholic Univ. of Korea, Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 3 16:20~16:35 The 1st National Strategic Plan for Viral Hepatitis B & C Control (2023-2027) ¾çÁø¼±(Áúº´°ü¸®Ã» °¨¿°º´°ü¸®°úÀå)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 3 16:35~16:50 Hepatitis B & C Elimination Strategy in Korea Chang Hun Lee(Jeonbuk National Univ., Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 3 16:50~17:05 Korean HCV Cohort Study and People Who Inject Drugs (PWID) in Korea Gwang Hyeon Choi(Seoul National Univ., Korea)
±³À°½Ã°£ 09¿ù 21ÀÏ ROOM 3 17:05~17:20 Korean HBV Cohort Study Jun Yong Park(Yonsei Univ., Korea)
Åä·Ð 09¿ù 21ÀÏ ROOM 3 17:20~17:40 Panel Discussion In Hee Kim, Young Chang, (Chonbuk National Univ., Korea, Soonchunhyang Univ., Korea)